In classical oncology, cancer development is often explained through a small handful of well-known, mutated oncogenes like RAS or MYC. However, tumor progression, metastasis, and immune evasion are frequently orchestrated by a much broader, hidden architecture of non-mutated molecules. Rather than acting as passive bystanders or mere biomarkers, a diverse array of circular RNAs (circRNAs), structural proteins, ion channels, and metabolic enzymes function as active drivers of malignancy when their expression levels are altered.
Understanding how these diverse components are hijacked reveals the underlying regulatory networks that sustain cancer hallmarks across different tissue types.
The Mechanics of Circular RNA Sponging Networks
One of the most prominent mechanisms driving tumor progression involves circular RNAs acting as competitive endogenous RNAs, or "molecular sponges."
To understand why this mechanism is so effective, consider the cell's default state of gene regulation. MicroRNAs (miRNAs) typically act as post-transcriptional brakes; they bind to specific messenger RNAs (mRNAs) to trigger their degradation or inhibit their translation, keeping oncogenic proteins in check. Circular RNAs, however, possess a covalently closed-loop structure that makes them highly resistant to exonuclease degradation. When a tumor cell overexpresses a specific circRNA, that molecule accumulates and presents multiple binding sites that sequester target miRNAs. By trapping these miRNAs, the circRNA effectively "sponges" them away from their natural mRNA targets, releasing the brakes and allowing downstream oncogenes to be translated at high volumes.
[Normal State] miRNA ──┤ Target mRNA (Oncogene Silenced)
[Malignant State] circRNA Overexpression ──> Sponges miRNA ──┤ (Target mRNA Free ──> Tumor Progression)
This regulatory cascade appears repeatedly across various malignancies:
- Breast Cancer: In triple-negative breast cancer, Lei Xing et al. demonstrated in The circRNA circIFI30 promotes progression of triple-negative breast cancer and correlates with prognosis that circIFI30 sponges miR-520b-3p. This action upregulates the well-known oncogene CD44, accelerating proliferation and metastasis.
- Colon Cancer: In circIFITM1/miR-802/Foxp1 Axis Participates in Proliferation and Invasion of Lovo Cells, Yu Wan et al. mapped how circIFITM1 sequesters miR-802 to elevate FOXP1 expression, directly driving colon cancer cell proliferation and invasion.
- Lung Cancer: Yi Dong et al. showed in [Effect of CircCCND1 on the Malignant Biological Behaviors of H446 Lung Cancer Cells by Regulating the MiR-340-5p/TGIF1 Axis] that elevated CircCCND1 downregulates miR-340-5p, which subsequently unleashes TGIF1 to promote aggressive phenotypes.
- Cervical Cancer: The clinical impact of this mechanism is highlighted by Xia Li et al. in Circular RNA circNRIP1 promotes migration and invasion in cervical cancer by sponging miR-629-3p and regulating the PTP4A1/ERK1/2 pathway. The authors found that circNRIP1 sponges miR-629-3p to activate the PTP4A1/ERK1/2 pathway, and its abundance directly correlates with lymphovascular space invasion—proving that these non-coding RNAs actively drive a tumor's ability to infiltrate the vascular and lymphatic systems.
- Esophageal and Colorectal Cancers: Similar axes operate via circ_0023984 sponging miR-134-5p to release CST4, as shown by Yang Ge et al. in CircRNA circ_0023984 promotes the progression of esophageal squamous cell carcinoma via regulating miR-134-5p/cystatin-s axis, and via circCCDC66 targeting miR-370 to elevate MDM4 expression, as detailed by Jie Chen et al. in Circular RNA CCDC66 Improves Murine Double Minute 4 (MDM4) Expression through Targeting miR-370 in Colorectal Cancer.
The functional necessity of this mechanism is confirmed when the system is inverted. In Circular RNA Circ_0000098 Elevates ALX4 Expression via Adsorbing miR-1204 to Inhibit the Progression of Hepatocellular Carcinoma, Ming Li et al. observed that when a protective circRNA (circ_0000098) is abnormally downregulated in liver cancer, miR-1204 is left free to suppress the tumor suppressor ALX4, thereby accelerating epithelial-mesenchymal transition (EMT) and malignant progression.
Hijacking Structural and Ion Channel Machinery
Beyond non-coding RNAs, tumors frequently overexpress structural proteins and ion channels that are normally reserved for basic cellular maintenance, co-opting them to serve as upstream oncogenic switches.
For example, structural maintenance of chromosomes (SMC) proteins are traditionally understood as nuclear scaffold components required for DNA organization. However, Bo Zhou et al. discovered in A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma that when the microRNA miR-219 is lost in liver cancer, the resulting overexpression of SMC4 acts as a direct oncogenic driver. Instead of merely organizing DNA, excess SMC4 triggers the JAK2/Stat3 signaling pathway, actively promoting cellular invasion and proliferation. Similarly, Yang Liu demonstrated in CKAP2 Regulated by TFDP1 Promotes Metastasis and Proliferation of Colorectal Cancer through Affecting the Tumor Microenvironment that Cytoskeleton Associated Protein 2 (CKAP2) is hijacked in colorectal cancer to drive EMT and remodel the surrounding tumor microenvironment.
Ion channels are similarly co-opted to alter intracellular biophysics. In Transient receptor potential canonical 1 is a candidate treatment target for tongue squamous cell carcinoma by inhibiting growth and invasion through phosphatidylinositol 3-kinase and protein kinase B pathway, Lei Jiang demonstrated that the TRPC1 calcium channel is heavily overexpressed in tongue squamous cell carcinoma. This overabundance of TRPC1 facilitates an influx of calcium ions that continuously activates the PI3K/AKT pathway, providing a ligand-independent growth signal that fuels tumor invasion.
This concept of ligand-independent activation is a recurring theme; Fang He et al. showed in Copper (II) Ions Activate Ligand-Independent Receptor Tyrosine Kinase (RTK) Signaling Pathway that environmental factors, such as copper (II) ions within the microenvironment, can directly trigger receptor tyrosine kinase (RTK) signaling pathways in the absence of natural growth factors, accelerating cancer cell migration.
Metabolic Reprogramming and Immune Evasion
To sustain rapid growth and survive in hostile environments, overexpressed drivers also rewire tumor metabolism and alter the immune landscape.
In hepatocellular carcinoma, Haiyang Yu et al. found in D-xylose suppresses hepatocellular carcinoma progression by regulating dihydrodiol dehydrogenase and remodeling the immune microenvironment that the enzyme Dihydrodiol dehydrogenase (DHDH) is significantly upregulated, actively promoting tumor progression and helping cells evade immune surveillance. This metabolic rewiring can also be driven by non-coding RNA interactions. For instance, Juanyi Shi et al. demonstrated in m 6 A‐Modified circRAPGEF1 Interaction with IGF2BP3 Promotes Hepatocellular Carcinoma Progression via Reprogramming Aspartate Metabolism that an $m^6A$-modified circular RNA, circRAPGEF1, binds directly to the RNA-binding protein IGF2BP3. This interaction alters aspartate metabolism and stabilizes liver cancer stem cells, driving aggressive tumor growth.
Other non-coding RNAs target metabolic pathways to prevent programmed cell death. In Novel evidence for oncogenic piRNA‐823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer, Muqing Yang et al. showed that piRNA-823 acts as an oncogenic driver by upregulating G6PD, which stabilizes HIF-1α and protects colorectal cancer cells from apoptosis. Similarly, enzymatic axes like the ZNF521/EBF1 pathway characterized by Yijiang Ni et al. in <scp>ZNF521</scp>/<scp>EBF1</scp> axis regulates <scp>AKR1B1</scp> to promote the proliferation, migration, and invasion of gastric cancer cells demonstrate that the upregulation of the metabolic enzyme AKR1B1 directly dictates the migratory and invasive capacity of gastric cancer cells.
Identifying Hub Genes for Targeted Therapy
By integrating large-scale transcriptomic data, Mendelian randomization, and functional validation, researchers can identify central "hub genes" that serve as critical vulnerabilities in these overexpressed networks. A pan-cancer analysis by Yanxing Li et al. in Multi-omics pan-cancer analyses identify MCM4 as a promising prognostic and diagnostic biomarker illustrated that the DNA replication protein MCM4 is universally upregulated across most major cancer types and is essential for cancer cell survival, making it a prime candidate for targeted therapies.
When these hub genes are identified, they open up precise therapeutic strategies:
- Colorectal Cancer: Yu Zhang et al. identified FUT8 as a central factor modulating the tumor immune microenvironment in Identification of hub gene associated with colorectal cancer: Integrating Mendelian randomization, transcriptome analysis and experimental verification, demonstrating that the drug candidate VE-822 can successfully target this axis to halt cell proliferation. Similarly, Qiang Feng et al. showed in CDC42EP3 promotes colorectal cancer through regulating cell proliferation, cell apoptosis and cell migration that depleting the overexpressed protein CDC42EP3 effectively halts colony formation and migration.
- Gastric and Pancreatic Cancers: In ISLR interacts with MGAT5 to promote the malignant progression of human gastric cancer AGS cells., Bin Zuo et al. proved that the overexpressed ISLR gene cooperates with the glycosylation enzyme MGAT5 to drive malignancy. Meanwhile, Honglin Li et al. established Epiphycan (EPYC) as a functional driver and prognostic biomarker in EPYC functions as a novel prognostic biomarker for pancreatic cancer.
- Prostate and Renal Cancers: Wei Li et al. demonstrated in Golgi phosphoprotein 3 regulates metastasis of prostate cancer via matrix metalloproteinase 9. that Golgi phosphoprotein 3 (GOLPH3) drives metastasis by upregulating matrix metalloproteinase 9 (MMP9). In clear cell renal cell carcinoma, Lu Zhang et al. identified CCL4 in Identification of CCL4 as an Immune-Related Prognostic Biomarker Associated With Tumor Proliferation and the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma as an immune-related driver correlating directly with advanced tumor grade and metastasis.
Ultimately, these studies demonstrate that tumor progression relies on a highly coordinated upregulation of non-coding RNAs and functional proteins. Mapping these specific regulatory axes moves oncology beyond generic biomarkers, providing precise molecular targets to disrupt the core machinery driving cancer malignancy.
Key Foundational Work
Bioinformatic analysis of the membrane cofactor protein CD46 and microRNA expression in hepatocellular carcinoma (2013) — contributed 1 concept elements to this direction.
A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma (2014) — contributed 1 concept elements to this direction.